[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100525115":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":21,"centralContacts":26,"locations":33,"responsibleParty":51,"collaborators":31,"id":53,"slug":54,"hasResults":55,"nctId":56,"briefTitle":57,"officialTitle":58,"acronym":31,"eligibilityCriteria":59,"healthyVolunteers":55,"sex":60,"minAge":61,"maxAge":31,"enrollmentInfo":62,"targetDuration":31,"studyType":65,"phases":66,"briefSummary":68,"conditions":69,"keywords":31,"overallStatus":36,"whyStopped":31,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":80},{"fullName":5,"class":6},"Shanghai Jiatan Pharmatech Co., Ltd","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"WX390","EXPERIMENTAL","Participants will receive WX390 continuous oral dosing (1.1 mg once a day).",[13],"Drug: WX390",[15],{"type":16,"name":9,"description":17,"armGroupLabels":18,"otherNames":19},"DRUG","WX390 tablet, 1.1 mg once a day",[9],[20],"WXFL10030390",[22],{"name":23,"affiliation":24,"role":25},"Xiaohua Wu, PhD","Fudan University","PRINCIPAL_INVESTIGATOR",[27],{"name":28,"role":29,"phone":30,"phoneExt":31,"email":32},"Jiajia Li","CONTACT","008621-64175590",null,"doc_lijiajia@163.com",[34],{"facility":35,"status":36,"city":37,"state":38,"zip":39,"country":40,"countryCode":41,"cosmosGeoPoint":42,"geoPoint":47,"contacts":48},"Fudan University Shanghai Cancer Center","RECRUITING","Shanghai","Shanghai Municipality","200000","China","CN",{"type":43,"coordinates":44},"Point",[45,46],121.45806,31.22222,{"lat":46,"lon":45},[49,50],{"name":23,"role":29,"phone":31,"phoneExt":31,"email":31},{"name":23,"role":25,"phone":31,"phoneExt":31,"email":31},{"type":52,"investigatorFullName":31,"investigatorTitle":31,"investigatorAffiliation":31,"oldNameTitle":31,"oldOrganization":31},"SPONSOR","100525115","phase-2-a-study-of-wx390-in-patients-with-advanced-solid-tumors-100525115",false,"NCT06117540","A Study of WX390 in Patients With Advanced Solid Tumors","An Open-label, Single-arm, Multicenter Phase II Clinical Study to Evaluate the Efficacy and Safety of WX390 in Patients With Advanced Solid Tumors","Inclusion Criteria:\n\n* ≥18 years of age\n* Histological or cytological confirmed advanced solid tumor, standard regimen failed\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0-1\n* Life expectancy of more than 3 months\n* At least one measurable lesion according to RECIST 1.1\n* Adequate organ function\n* Signed and dated informed consent\n\nExclusion Criteria:\n\n* Anti-cancer therapy within 30 days prior to the initiation of investigational treatment\n* Major surgery within 30 days prior to the initiation of study treatment\n* Toxicity from a previous anti-tumor treatment that does not return to Grade 0 or 1 (except for alopecia)\n* Patients who are suffering active interstitial lung disease\n* Evidence of ongoing or active serious infection\n* Received corticosteroids treatment or other immunodepressant within 2 weeks before the first dose of study treatment\n* Active hepatitis B or C infection\n* Inability to take medication orally\n* Abuse of alcohol or drugs\n* Pregnant or lactating women\n* People with cognitive and psychological abnormality or with low compliance","FEMALE","18 Years",{"count":63,"type":64},70,"ESTIMATED","INTERVENTIONAL",[67],"PHASE2","The goal of this clinical trial is to evaluate the efficacy and safety of WX390 in patients with advanced solid tumors. The main questions it aims to answer are:\n\n* PFS, OS, DoR at week 48;\n* antitumor effects at week 24 and week 48. Participants will be treated with WX390 orally, and follow the efficacy and safety evaluation according to the protocol.",[70],"Solid Tumor","2024-11-18",{"date":73,"type":74},"2024-11-19","ACTUAL",{"date":76,"type":74},"2021-05-11",{"date":78,"type":64},"2026-06-12",{"name":5,"class":6},1]